161 related articles for article (PubMed ID: 27058903)
1. A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability.
Cantisani MC; Parascandolo A; Perälä M; Allocca C; Fey V; Sahlberg N; Merolla F; Basolo F; Laukkanen MO; Kallioniemi OP; Santoro M; Castellone MD
Oncotarget; 2016 May; 7(19):28510-22. PubMed ID: 27058903
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
3. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
4. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
6. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
[TBL] [Abstract][Full Text] [Related]
7. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells.
Gilbert-Sirieix M; Ripoche H; Malvy C; Massaad-Massade L
Thyroid; 2010 Oct; 20(10):1053-65. PubMed ID: 20615140
[TBL] [Abstract][Full Text] [Related]
8. RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.
De Falco V; Castellone MD; De Vita G; Cirafici AM; Hershman JM; Guerrero C; Fusco A; Melillo RM; Santoro M
Cancer Res; 2007 Jan; 67(1):381-90. PubMed ID: 17210721
[TBL] [Abstract][Full Text] [Related]
9. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
[TBL] [Abstract][Full Text] [Related]
10. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
11. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
12. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
13. BRAF is a therapeutic target in aggressive thyroid carcinoma.
Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
[TBL] [Abstract][Full Text] [Related]
14. Identification of targets of Twist1 transcription factor in thyroid cancer cells.
Di Maro G; Orlandella FM; Bencivenga TC; Salerno P; Ugolini C; Basolo F; Maestro R; Salvatore G
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1617-26. PubMed ID: 24848707
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas.
Rahman MA; Salajegheh A; Smith RA; Lam AK
Endocrine; 2016 Oct; 54(1):129-138. PubMed ID: 27179656
[TBL] [Abstract][Full Text] [Related]
16. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
Lodyga M; De Falco V; Bai XH; Kapus A; Melillo RM; Santoro M; Liu M
Oncogene; 2009 Feb; 28(7):937-49. PubMed ID: 19060924
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
Ciampi R; Knauf JA; Kerler R; Gandhi M; Zhu Z; Nikiforova MN; Rabes HM; Fagin JA; Nikiforov YE
J Clin Invest; 2005 Jan; 115(1):94-101. PubMed ID: 15630448
[TBL] [Abstract][Full Text] [Related]
18. CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells.
De Falco V; Tamburrino A; Ventre S; Castellone MD; Malek M; Manié SN; Santoro M
Cancer Res; 2012 Mar; 72(6):1449-58. PubMed ID: 22271686
[TBL] [Abstract][Full Text] [Related]
19. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components.
Mochizuki K; Kondo T; Nakazawa T; Iwashina M; Kawasaki T; Nakamura N; Yamane T; Murata S; Ito K; Kameyama K; Kobayashi M; Katoh R
Histopathology; 2010 Sep; 57(3):444-50. PubMed ID: 20840674
[TBL] [Abstract][Full Text] [Related]
20. KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in thyroid cancer.
Lee J; Seol MY; Jeong S; Kwon HJ; Lee CR; Ku CR; Kang SW; Jeong JJ; Shin DY; Nam KH; Lee EJ; Chung WY; Jo YS
J Mol Endocrinol; 2015 Apr; 54(2):115-24. PubMed ID: 25608512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
